Azitra, Inc. (AZTR)

NYSE Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$10.1M
Cash & Equivalents
$2.5M
Quarterly Burn Rate
12 mo
Est. Cash Runway
$2M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2027-01-15 Phase2 Readout —

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06830863 A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity PHASE2 Recruiting 32
NCT06137157 Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome PHASE1 Recruiting 12

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-06-17 8-K Azitra, Inc. (AZTR) (CIK 0001701478) - EX-99.1 EDGAR
2026-06-04 8-K Azitra, Inc. (AZTR) (CIK 0001701478) - EX-99.1 EDGAR
2026-05-27 8-K Azitra, Inc. (AZTR) (CIK 0001701478) - EX-99.1 EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for AZTR.

SEC EDGAR Filings

All SEC filings for Azitra, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.